Literature DB >> 6184150

Modulation of 5-fluorouracil-induced toxicity in mice with interferon or with the interferon inducer, polyinosinic-polycytidylic acid.

R L Stolfi, D S Martin, R C Sawyer, S Spiegelman.   

Abstract

Partially purified preparations of mouse interferon, administered during the 2-day period following the administration of a toxic dose of 5-fluorouracil (FUra), yielded significant protection from mortality in BALB/c X DBA/2 F1 mice. Protection against FUra-induced toxicity was also observed when the interferon inducer polyinosinic-polycytidylic acid (poly I X poly C) was administered with FUra. The temporal relationship between the administration of poly I X poly C and FUra was found to be a critical determinant of the intensity of toxic manifestations. In relation to FUra alone, poly I X poly C could enhance (when administered 48 hr before FUra), diminish (when administered together with FUra), or not affect (when administered 48 hr after FUra) the degree of resultant toxicity. Cytofluorometric analysis of the DNA content of bone marrow cells indicated a transient period (about 42 hr) of inhibition of cell cycling following the administration of poly I X poly C, followed by reentry into cycle (between 42 and 66 hr) and a return to normal cycle phase distribution by 90 hr. This disturbance of the kinetic pattern of cell cycling in bone marrow would explain the administration time-dependent variability of the effect of poly I X poly C on FUra toxicity, since FUra is known to be a cell cycle-specific cytotoxic drug. Potential practical application of this observation to the clinical use of FUra in cancer therapy is discussed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6184150

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  Drug treatment of colorectal cancer. Current status.

Authors:  L Saltz
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

2.  Combined effect of 5-fluorouracil and interferon on experimental liver metastases of rat colon carcinoma.

Authors:  R L Marquet; J Jeekel
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

3.  Double modulation of 5-fluorouracil by high-dose leucovorin and interferon alpha 2b in advanced colorectal cancer: a phase I and a phase II study of weekly administration.

Authors:  G G Steger; R M Mader; M P Djavanmard; M F Gnant; G Locker; C Marosi; H Rainer; R Jakesz
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

4.  Pharmacokinetic interaction of 5-fluorouracil and interferon alpha-2b with or without folinic acid.

Authors:  J b1p6uller; M Czejka
Journal:  Med Oncol       Date:  1995-03       Impact factor: 3.064

5.  A phase II trial of interferon alpha-2A plus fluorouracil in advanced renal cell carcinoma. A Hoosier Oncology Group study.

Authors:  B R Murphy; S M Rynard; L H Einhorn; P J Loehrer
Journal:  Invest New Drugs       Date:  1992-08       Impact factor: 3.850

Review 6.  New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: Thymidylate synthase.

Authors:  C L van der Wilt; G J Peters
Journal:  Pharm World Sci       Date:  1994-04-15

7.  Effective treatment of liver metastases from colon cancer with a combination of gamma-interferon and cisplatin chemotherapy: report of a case.

Authors:  N Kohara; F Kitaoka; K Komuta; M Yamamoto; K Motojima; T Kanematsu
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

8.  A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma.

Authors:  A Rohatiner; J Radford; D Deakin; H Earl; S B Love; O Price; A Wilson; T A Lister
Journal:  Br J Cancer       Date:  2001-07-06       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.